{"protocol":{"minReaderVersion":1,"minWriterVersion":2,"readerFeatures":null,"writerFeatures":null}}
{"metaData":{"id":"bb255ca4-c6ff-41a8-a313-0251caf3dab6","name":null,"description":null,"format":{"provider":"parquet","options":{}},"schemaString":"{\"type\":\"struct\",\"fields\":[{\"name\":\"title\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"description\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"published date\",\"type\":\"date\",\"nullable\":true,\"metadata\":{}},{\"name\":\"url\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"publisher\",\"type\":{\"type\":\"struct\",\"fields\":[{\"name\":\"href\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"title\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}}]},\"nullable\":true,\"metadata\":{}},{\"name\":\"query\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"query end date\",\"type\":\"timestamp\",\"nullable\":true,\"metadata\":{}},{\"name\":\"published datetime\",\"type\":\"timestamp\",\"nullable\":true,\"metadata\":{}},{\"name\":\"published date str\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"article text\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"article html\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"article summary\",\"type\":\"string\",\"nullable\":true,\"metadata\":{}},{\"name\":\"article keywords\",\"type\":{\"type\":\"array\",\"elementType\":\"string\",\"containsNull\":true},\"nullable\":true,\"metadata\":{}}]}","partitionColumns":["query","published date str"],"createdTime":1701916333309,"configuration":{}}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-07/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","partitionValues":{"published date str":"2023-12-07","query":"Ozempic Eli Lilly"},"size":48833,"modificationTime":1701916333296,"dataChange":true,"stats":"{\"numRecords\": 1, \"minValues\": {\"title\": \"Health Canada Collaborates with Manufacturers to Address Diabetes Drug Shortage - Express Healthcare Management\", \"description\": \"Health Canada Collaborates with Manufacturers to Address Diabetes Drug Shortage  Express Healthcare Management\", \"published date\": \"2023-12-07\", \"url\": \"https://news.google.com/rss/articles/CBMibmh0dHBzOi8vd3d3LmV4cHJlc3NoZWFsdGhjYXJlbWdtdC5jb20vbmV3czIvaGVhbHRoLWNhbmFkYS1zYXlzLW96ZW1waWMtc2hvcnRhZ2VzLXRvLWNvbnRpbnVlLWludG8tMjAyNC80MzI1ODUv0gEA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.expresshealthcaremgmt.com\", \"publisher.title\": \"Express Healthcare Management\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-07T00:16:11\", \"article text\": \"Health Canada is taking action to address the global shortage of diabetes drugs, including Ozempic, caused by high demand. The shortage is expected to last until early 2024, creating challenges for patients in Canada. Health Canada is working closely with Novo Nordisk, the company that markets Ozempic, as well as Eli Lilly, the company that markets Trulicity and Mounjaro, to increase manufacturing capacity and ensure a steady supply of these crucial medications.\\n\\nWhile efforts are underway to ramp up production, it will take time to meet the increased demand for these diabetes drugs. In the meantime, Health Canada has advised healthcare providers not to initiate new patients on these medications, unless there are no suitable alternatives and there is a clinical necessity to do so. This is to ensure that the available supply is conserved for patients who have no other treatment options.\\n\\nBoth Novo Nordisk and Eli Lilly have requested that pharmacists limit refill prescriptions to a 30-day supply, further emphasizing the need to conserve these drugs for those who rely on them. These medications are often prescribed for weight loss, making it essential to prioritize patients who have no other effective treatment choices.\\n\\nHealth Canada acknowledges the impact of the shortage on individuals with diabetes and is committed to working with manufacturers to alleviate the situation. The agency is actively exploring strategies to increase manufacturing capacity and improve access to these drugs. However, it is crucial for healthcare providers to carefully evaluate alternatives and prioritize patients\\u2019 wellbeing while managing the limited supply. Collaborative efforts between regulatory bodies, manufacturers, and healthcare professionals will be key in navigating this challenging period and ensuring the availability of diabetes drugs for all patients in need.\", \"article summary\": \"Health Canada is taking action to address the global shortage of diabetes drugs, including Ozempic, caused by high demand.\\nThe shortage is expected to last until early 2024, creating challenges for patients in Canada.\\nWhile efforts are underway to ramp up production, it will take time to meet the increased demand for these diabetes drugs.\\nHealth Canada acknowledges the impact of the shortage on individuals with diabetes and is committed to working with manufacturers to alleviate the situation.\\nCollaborative efforts between regulatory bodies, manufacturers, and healthcare professionals will be key in navigating this challenging period and ensuring the availability of diabetes drugs for all patients in need.\", \"article keywords.list.item\": \"address\"}, \"maxValues\": {\"title\": \"Health Canada Collaborates with Manufacturers to Address Diabetes Drug Shortage - Express Healthcare Management\", \"description\": \"Health Canada Collaborates with Manufacturers to Address Diabetes Drug Shortage  Express Healthcare Management\", \"published date\": \"2023-12-07\", \"url\": \"https://news.google.com/rss/articles/CBMibmh0dHBzOi8vd3d3LmV4cHJlc3NoZWFsdGhjYXJlbWdtdC5jb20vbmV3czIvaGVhbHRoLWNhbmFkYS1zYXlzLW96ZW1waWMtc2hvcnRhZ2VzLXRvLWNvbnRpbnVlLWludG8tMjAyNC80MzI1ODUv0gEA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.expresshealthcaremgmt.com\", \"publisher.title\": \"Express Healthcare Management\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-07T00:16:11\", \"article text\": \"Health Canada is taking action to address the global shortage of diabetes drugs, including Ozempic, caused by high demand. The shortage is expected to last until early 2024, creating challenges for patients in Canada. Health Canada is working closely with Novo Nordisk, the company that markets Ozempic, as well as Eli Lilly, the company that markets Trulicity and Mounjaro, to increase manufacturing capacity and ensure a steady supply of these crucial medications.\\n\\nWhile efforts are underway to ramp up production, it will take time to meet the increased demand for these diabetes drugs. In the meantime, Health Canada has advised healthcare providers not to initiate new patients on these medications, unless there are no suitable alternatives and there is a clinical necessity to do so. This is to ensure that the available supply is conserved for patients who have no other treatment options.\\n\\nBoth Novo Nordisk and Eli Lilly have requested that pharmacists limit refill prescriptions to a 30-day supply, further emphasizing the need to conserve these drugs for those who rely on them. These medications are often prescribed for weight loss, making it essential to prioritize patients who have no other effective treatment choices.\\n\\nHealth Canada acknowledges the impact of the shortage on individuals with diabetes and is committed to working with manufacturers to alleviate the situation. The agency is actively exploring strategies to increase manufacturing capacity and improve access to these drugs. However, it is crucial for healthcare providers to carefully evaluate alternatives and prioritize patients\\u2019 wellbeing while managing the limited supply. Collaborative efforts between regulatory bodies, manufacturers, and healthcare professionals will be key in navigating this challenging period and ensuring the availability of diabetes drugs for all patients in need.\", \"article summary\": \"Health Canada is taking action to address the global shortage of diabetes drugs, including Ozempic, caused by high demand.\\nThe shortage is expected to last until early 2024, creating challenges for patients in Canada.\\nWhile efforts are underway to ramp up production, it will take time to meet the increased demand for these diabetes drugs.\\nHealth Canada acknowledges the impact of the shortage on individuals with diabetes and is committed to working with manufacturers to alleviate the situation.\\nCollaborative efforts between regulatory bodies, manufacturers, and healthcare professionals will be key in navigating this challenging period and ensuring the availability of diabetes drugs for all patients in need.\", \"article keywords.list.item\": \"working\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 0, \"article html\": 0, \"article summary\": 0, \"article keywords.list.item\": 0}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-06/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","partitionValues":{"published date str":"2023-12-06","query":"Ozempic Eli Lilly"},"size":223889,"modificationTime":1701916333308,"dataChange":true,"stats":"{\"numRecords\": 3, \"minValues\": {\"title\": \"GlucoTrim Reviews - Scam or Safe Gluco Trim Glucose Modulator Formula for High Blood Sugar? - Islands' Weekly\", \"description\": \"GlucoTrim Reviews - Scam or Safe Gluco Trim Glucose Modulator Formula for High Blood Sugar?  Islands' Weekly\", \"published date\": \"2023-12-06\", \"url\": \"https://news.google.com/rss/articles/CBMiSmh0dHBzOi8vYmVzdGxpZmVvbmxpbmUuY29tL3plcGJvdW5kLWhpdHMtcGhhcm1hY2llcy1vemVtcGljLXNob3J0YWdlLW5ld3Mv0gEA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://bestlifeonline.com\", \"publisher.title\": \"Best Life\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-06T09:30:00\", \"article summary\": \"But now, the new weight loss drug Zepbound has hit U.S. pharmacies, which could potentially help alleviate some issues amid an Ozempic shortage.\\nThe weight loss drug Zepbound is now available for prescription.\\nThe booming weight loss medication market just got a little more robust.\\nThe prescription weight loss medication is hitting shelves roughly a month after the U.S. Food & Drug Administration (FDA) issued its approval.\\nBut others also hope that it could help to reduce the cost of weight loss drugs in general.\", \"article keywords.list.item\": \"2024\"}, \"maxValues\": {\"title\": \"Zepbound Hits U.S. Pharmacies Amid Ozempic Shortage - Best Life\", \"description\": \"Zepbound Hits U.S. Pharmacies Amid Ozempic Shortage  Best Life\", \"published date\": \"2023-12-06\", \"url\": \"https://news.google.com/rss/articles/CBMifGh0dHBzOi8vd3d3LmlzbGFuZHN3ZWVrbHkuY29tL2Jsb2cvZ2x1Y290cmltLXJldmlld3Mtc2NhbS1vci1zYWZlLWdsdWNvLXRyaW0tZ2x1Y29zZS1tb2R1bGF0b3ItZm9ybXVsYS1mb3ItaGlnaC1ibG9vZC1zdWdhci_SAQA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.islandsweekly.com\", \"publisher.title\": \"Islands' Weekly\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-06T23:50:00\", \"article summary\": \"Send this page to someone via emailHealth Canada says it is working with manufacturers to make diabetes drugs, including Ozempic, more available during a worldwide shortage fuelled by high demand that\\u2019s expected to last into the new year.\\nIt says Novo Nordisk, which markets Ozempic, is expecting a shortage in Canada of the 0.25 mg, 0.5 mg and 1 mg injection pens until early 2024.\\nEli Lilly, which markets Trulicity and Mounjaro, is also expecting lower supplies of both drugs throughout early 2024.\\n2:16 Discrimination preventing coverage of effective weight loss drugsHealth Canada says efforts are being made to increase manufacturing capacity but it will take time to build up supply levels.\\nThe regulator says the drugs, often used for weight loss, should be conserved for people who have no other treatment choices as both drug companies are asking pharmacists to limit refill prescriptions to a 30-day supply.\", \"article keywords.list.item\": \"zepbound\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 0, \"article html\": 0, \"article summary\": 0, \"article keywords.list.item\": 0}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"add":{"path":"query=Ozempic%2520Eli%2520Lilly/published date str=2023-12-05/0-590aea05-cc70-41b0-acdd-2f6edf2e9588-0.parquet","partitionValues":{"query":"Ozempic Eli Lilly","published date str":"2023-12-05"},"size":411792,"modificationTime":1701916333309,"dataChange":true,"stats":"{\"numRecords\": 4, \"minValues\": {\"title\": \"Beyond Ozempic: Where Are the Opportunities for Gains in Weight Loss Stocks? - RealMoney\", \"description\": \"Beyond Ozempic: Where Are the Opportunities for Gains in Weight Loss Stocks?  RealMoney\", \"published date\": \"2023-12-05\", \"url\": \"https://news.google.com/rss/articles/CBMiQGh0dHBzOi8vdGhlbWVzc2VuZ2VyLmNvbS9oZWFsdGgvemVwYm91bmQtYXZhaWxhYmxlLWluLXBoYXJtYWNpZXPSAQA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://realmoney.thestreet.com\", \"publisher.title\": \"AboutLawsuits.com\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-05T17:00:17\", \"article text\": \"Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues.\\n\\nZepbound is the latest entrant to the budding weight loss drug market, which Wall Street expects to grow to about $100 billion by the end of the decade.\\n\\nHigh demand for the treatments has resulted in widespread shortages of Novo Nordisk 's Wegovy and diabetes drug Ozempic as well as Eli Lilly's diabetes treatment Mounjaro, pushing companies to ramp up production. Those ongoing supply issues give Zepbound, which contains the same active ingredient as Mounjaro, an opportunity to capture market share.\\n\\nEli Lilly also said in a release that its commercial savings card program, which aims to expand access to Zepbound, is now available to patients with a prescription.\\n\\nUnder the program, patients whose health insurance covers Zepbound may pay as low as $25 for a one- or three-month prescription of the weekly injection. Those whose insurance does not cover Zepbound may pay as low as $550 for a one-month prescription \\u2014 about half the drug's list price.\\n\\nAlso on Tuesday, Eli Lilly said Zepbound was added to the preferred formulary, or list of covered drugs, of a major drug benefits company, Cigna .\\n\\nZepbound will be added to the commercial formularies of Cigna's health-care business on Dec. 15, according to Eli Lilly.\\n\\n\\\"The availability of Zepbound in U.S. pharmacies is the first step, but we have to work hand-in-hand with employers, government and healthcare industry partners to remove barriers and make Zepbound available to those who need it,\\\" said Rhonda Pacheco, Eli Lilly's group vice president for diabetes and obesity, in a statement.\\n\\nZepbound is an injection administered once weekly. The dosage must be increased over a period of four to 20 weeks to achieve the target dose sizes of 5, 10 or 15 milligrams per week.\\n\\nThe drug works by activating two naturally produced hormones in the body: glucagon-like peptide 1, known as GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP.\\n\\nThe combination is said to slow the emptying of the stomach, making people feel full for longer and suppressing appetite by slowing hunger signals in the brain.\\n\\n\\n\\nDon't miss these stories from CNBC PRO:\", \"article summary\": \"Eli Lilly on Tuesday said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S., serving as an alternative to rival obesity drugs such as Wegovy that are facing supply issues.\\nHigh demand for the treatments has resulted in widespread shortages of Novo Nordisk 's Wegovy and diabetes drug Ozempic as well as Eli Lilly's diabetes treatment Mounjaro, pushing companies to ramp up production.\\nEli Lilly also said in a release that its commercial savings card program, which aims to expand access to Zepbound, is now available to patients with a prescription.\\nAlso on Tuesday, Eli Lilly said Zepbound was added to the preferred formulary, or list of covered drugs, of a major drug benefits company, Cigna .\\nZepbound will be added to the commercial formularies of Cigna's health-care business on Dec. 15, according to Eli Lilly.\", \"article keywords.list.item\": \"approved\"}, \"maxValues\": {\"title\": \"Newly Approved Weight Loss Drug Now Available in US - The Messenger\", \"description\": \"Newly Approved Weight Loss Drug Now Available in US  The Messenger\", \"published date\": \"2023-12-05\", \"url\": \"https://news.google.com/rss/articles/CBMifmh0dHBzOi8vcmVhbG1vbmV5LnRoZXN0cmVldC5jb20vaGVhbHRoY2FyZS9iZXlvbmQtb3plbXBpYy13aGVyZS1hcmUtdGhlLW9wcG9ydHVuaXRpZXMtZm9yLWdhaW5zLWluLXdlaWdodC1sb3NzLXN0b2Nrcy0xNjEzOTQxN9IBAA?oc=5&hl=en-US&gl=US&ceid=US:en\", \"publisher.href\": \"https://www.cnbc.com\", \"publisher.title\": \"The Messenger\", \"query end date\": \"2023-12-07T02:31:35.152051\", \"published datetime\": \"2023-12-05T21:59:00\", \"article text\": \"Zepbound, Eli Lilly\\u2019s answer to the blockbuster drugs Ozempic and Wegovy, is now available by prescription in American pharmacies, according to a press release from the company.\\n\\nPeople who have health insurance that includes Zepbound could pay as little as $25 for a one to three month prescription, Lilly said in a release. However, people without health insurance, or those whose plans don\\u2019t cover the drug, can expect to pay at least $550 per month\\u2014and this is for people who have access to the company\\u2019s savings card program. The list price, according to the company, will be $1,060 for a month\\u2019s prescription.\\n\\nThe drug\\u2019s main ingredient, tirzapetide, is also used in the Indianapolis-based company\\u2019s popular type 2 diabetes drug, Mounjaro. Like its major competitor \\u2013 semaglutide, which is behind Ozempic and Mounjaro \\u2013 tirzapetide was initially developed to treat type 2 diabetes only for users to also experience significant weight loss as side effect while using it.\\n\\nSome studies have found that tirzapetide is more effective in helping patients lose weight than Ozempic and Wegovy.\\n\\nOzempic has been in short supply due to sky-high demand, now that its ability to treat obesity is becoming more widely known. Novo Nordisk, the manufacturer of semaglutide, has been rationing starter kits of the drug as it struggles to produce enough.\\n\\nAccording to the Food and Drug Administration, tirzapetide is also in shortage, but the list says that all dosages are \\u201cavailable.\\u201d\", \"article summary\": \"Zepbound, Eli Lilly\\u2019s answer to the blockbuster drugs Ozempic and Wegovy, is now available by prescription in American pharmacies, according to a press release from the company.\\nThe drug\\u2019s main ingredient, tirzapetide, is also used in the Indianapolis-based company\\u2019s popular type 2 diabetes drug, Mounjaro.\\nSome studies have found that tirzapetide is more effective in helping patients lose weight than Ozempic and Wegovy.\\nNovo Nordisk, the manufacturer of semaglutide, has been rationing starter kits of the drug as it struggles to produce enough.\\nAccording to the Food and Drug Administration, tirzapetide is also in shortage, but the list says that all dosages are \\u201cavailable.\\u201d\", \"article keywords.list.item\": \"zepbound\"}, \"nullCount\": {\"title\": 0, \"description\": 0, \"published date\": 0, \"url\": 0, \"publisher.href\": 0, \"publisher.title\": 0, \"query end date\": 0, \"published datetime\": 0, \"article text\": 1, \"article html\": 1, \"article summary\": 1, \"article keywords.list.item\": 1}}","tags":null,"deletionVector":null,"baseRowId":null,"defaultRowCommitVersion":null,"clusteringProvider":null}}
{"commitInfo":{"timestamp":1701916333310,"operation":"CREATE TABLE","operationParameters":{"location":"file:///workspaces/article-rebuttal-agent/notebooks/data/articles-ingest","metadata":"{\"configuration\":{},\"created_time\":1701916333309,\"description\":null,\"format\":{\"options\":{},\"provider\":\"parquet\"},\"id\":\"bb255ca4-c6ff-41a8-a313-0251caf3dab6\",\"name\":null,\"partition_columns\":[\"query\",\"published date str\"],\"schema\":{\"fields\":[{\"metadata\":{},\"name\":\"title\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"description\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"published date\",\"nullable\":true,\"type\":\"date\"},{\"metadata\":{},\"name\":\"url\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"publisher\",\"nullable\":true,\"type\":{\"fields\":[{\"metadata\":{},\"name\":\"href\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"title\",\"nullable\":true,\"type\":\"string\"}],\"type\":\"struct\"}},{\"metadata\":{},\"name\":\"query\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"query end date\",\"nullable\":true,\"type\":\"timestamp\"},{\"metadata\":{},\"name\":\"published datetime\",\"nullable\":true,\"type\":\"timestamp\"},{\"metadata\":{},\"name\":\"published date str\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"article text\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"article html\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"article summary\",\"nullable\":true,\"type\":\"string\"},{\"metadata\":{},\"name\":\"article keywords\",\"nullable\":true,\"type\":{\"containsNull\":true,\"elementType\":\"string\",\"type\":\"array\"}}],\"type\":\"struct\"}}","mode":"ErrorIfExists","protocol":"{\"minReaderVersion\":1,\"minWriterVersion\":2,\"readerFeatures\":null,\"writerFeatures\":null}"},"clientVersion":"delta-rs.0.17.0"}}